Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

Guy Boivin a,b,*, Georges Caouette b,c, Line Frenette b,c, Julie Carbonneau a, Manale Ouakki d, Gaston De Serres b,d

a Research Center in Infectious Diseases, CHUQ-CHUL, Quebec City, QC, Canada
b Laval University, Quebec City, QC, Canada
c Sainte-Foy Pediatric Clinic, Quebec City, Canada
d Public Health Research Unit, Quebec City, QC, Canada

Received 5 June 2007; received in revised form 12 November 2007; accepted 14 November 2007

Abstract

Background: Palivizumab is a humanized monoclonal antibody that prevents severe human respiratory syncytial virus (HRSV) infections.

Objectives: We determined the etiology of respiratory viral infections in palivizumab recipients, and monitored the clinical outcome and HRSV genotype in HRSV-infected infants.

Study design: Nasopharyngeal aspirates (NPAs) were collected from children receiving palivizumab who consulted or were hospitalized for acute respiratory tract infection (ARTI) during the 2004–2005 season. Viral cultures and multiplex RT-PCR for influenza A/B, HRSV and human metapneumovirus were performed. The fusion (F) gene of HRSV amplicons was also sequenced.

Results: Among 116 enrolled patients, 51 (44%) had ≥1 episode of ARTI for a total of 93 visits. At least one virus was identified in 33 (36%) of the 93 NPA samples; HRSV accounted for 11 (33%) of confirmed viral etiologies. Compared to subjects who had other viral ARTI, HRSV-positive subjects had less fever (p = 0.01) and tended to have more bronchiolitis (p = 0.07). Ten subjects (11 visits) developed HRSV infection, although only one was hospitalized. HRSV was detected after a median of 5.5 palivizumab doses and a median of 14 days after the last dose. One of the 11 HRSV strains tested had a F mutation located in the palivizumab-binding site.

Conclusion: HRSV is still a major cause of ARTI in children receiving palivizumab, although the outcome of infected children appears mild.

Keywords: Human respiratory syncytial virus; Palivizumab; Resistance

1. Introduction

Human respiratory syncytial virus (HRSV) is a major cause of lower respiratory tract infection in premature babies, infants less than 6 months old and elderly institutionalized subjects (Greenough, 2002; Welliver, 2003). Although, only 1% of HRSV-infected infants require hospitalization, such infections are associated with 50–90% of hospitalizations attributable to bronchiolitis, and 20–50% of hospitalizations attributable to pneumonia (Ogra, 2004). In the US, it has been estimated that HRSV infections account for approximately 90,000 hospitalizations and 4000–17,000 deaths yearly (Ogra, 2004; Thompson et al., 2003).

Palivizumab (Synagis, MedImmune Inc., Gaithersburg, MD) is a humanized monoclonal antibody directed against the HRSV fusion (F) glycoprotein (Johnson et al., 1997; Meissner, 2003). Palivizumab is recommended during the HRSV season for premature babies (≤32 weeks of gestation and a subset of those between 32 and 35 weeks) and infants <2 years of age with chronic lung problems or congenital heart disease (Feltes et al., 2003; The IMpact-RSV Study Group, 1998).

Despite the increased use of palivizumab, there is a paucity of data regarding the impact of such immunoprophylaxis on the viral etiology of acute respiratory tract infections (ARTIs)
in treated infants. The purpose of this study was 2-fold: to determine viral etiologies of both upper and lower respiratory tract infections in palivizumab recipients; and to monitor the clinical outcome and the viral F protein genotype in HRSV-infected infants.

2. Materials and methods

2.1. Study design

Parents of all infants who received at least 1 dose of palivizumab during the 2004–2005 HRSV season at a large private pediatric clinic in Québec City, QC, Canada were invited to participate. Informed consent was obtained for 90% of eligible participants (a few patients living in remote areas were not enrolled), and demographic and medical questionnaires were completed. Parents were advised to contact a research nurse whenever their child was experiencing a respiratory tract infection (with or without fever) severe enough to warrant medical evaluation. When contacted, the research nurse scheduled a medical appointment on the same day at the clinic (week days) or told the parents to consult at the emergency room of the Québec City pediatric hospital (weekends and holidays). At both sites, physicians were instructed to collect a nasopharyngeal aspirate (NPA) for virological analyses and to fill out a questionnaire on clinical symptoms. In addition, at monthly intervals (at the time of palivizumab administration), parents were asked about consultations or hospitalizations of their child. The study was approved by the ethics committee of the Centre hospitalier universitaire de Québec.

2.2. Virological analyses

An aliquot (500 μl) of each NPA was diluted 1:1 in Hanks medium and inoculated on the day of collection on a panel of ten continuous cell lines for viral cultures as previously described (Boivin et al., 2003). Respiratory viruses typically identified by cell culture in this laboratory include: influenza A and B, parainfluenza (PIV) 1–4, HRSV, human metapneumovirus (HMPV) and adenoviruses. In addition, a second aliquot (200 μl) of the NPA was reserved for a multiplex real-time PCR assay that amplifies influenza A/B, parainfluenza (PIV) 1–4, HRSV, human metapneumovirus (HMPV) using transcribed plasmids. The lower limit of detection for the multiplex assay was 10 copies for influenza A/B, 100 copies for HRSV and 50 copies for HMPV using transcribed plasmids. The entire F gene sequence was determined from amplicons from each HRSV-positive specimen and was aligned with corresponding sequences of the A2 strain (GenBank accession...
number M11486) for genotype A viruses or with the B1 strain (GenBank accession number AF013254) for genotype B viruses.

2.3. Statistical analyses

Proportions were compared using the Fisher’s exact test. Means were compared using the Kruskal–Wallis test. All tests of statistical significance were two-tailed and significance was set at the 5% level. The SAS Institute software (version 9.1) was used for data statistical analysis.

3. Results

3.1. Demographic and clinical characteristics of the population

A total of 116 infants who received at least 1 dose of palivizumab were recruited in the study (Table 1). The mean age at birth was 32.2 weeks. The indication for palivizumab was prematurity <33 weeks for 75 (64.7%), prematurity between 33 and 35 weeks with risk factors for 17 (14.7%), pulmonary conditions only for 7 (6.0%), cardiac conditions only for 7 (6.0%), and other conditions for 10 (8.6%). Seven premature children also had cardio-pulmonary conditions. A total of 44.0% of the subjects had at least one underlying disease and 4.3% were receiving chronic oxygen therapy at the beginning of the study. The mean age at the first dose of palivizumab was 5.1 months and the mean number of doses of palivizumab received per participant during the 2004–2005 HRSV season was 5.7 (range: 1–8). An interval of ≤30 days between palivizumab injections occurred for 84% of 114 patients between the first and second dose; 94.5% of 109 patients between the second and third dose; 91% of 101 patients between the third and fourth dose; 93.5% of 92 patients between the fourth and fifth dose; 96% of 79 patients between the fifth and sixth dose; 98% of 45 patients between the sixth and seventh dose; and 100% of 2 patients between the seventh and eighth dose.

3.2. Consultations and hospitalizations for ARTI

Among the 116 patients enrolled in the study, 51 (44%) consulted for ARTI for a total of 93 visits (78 outpatient consultations and 50% of hospitalizations); a bronchiolitis (defined clinically) for 40% of visits (42% of outpatient consultations and 29% of hospitalizations); and pneumonitis (defined by new infiltrates on chest X-ray) for 3.3% of visits (1.3% of outpatient consultations and 14% of hospitalizations, p = 0.06). Other diagnoses reported included otitis media (6.7%), pharyngitis (4.4%), croup (3.3%) and a flu-like illness (3.3%).

3.3. Virological findings

At least one virus was identified by viral culture and/or by multiplex real-time RT-PCR in 33 (35.5%) of the 93 NPA specimens collected. Among the viruses identified, there were 11 HRSVs (10 by RT-PCR and 6 by culture), 8 PIVs (4 PIV-3, 2 PIV-1 and 2 PIV-4 by culture), 5 HMPVs (5 by RT-PCR and 3 by culture), 5 adenoviruses (by culture), 2 influenza A (by both RT-PCR and culture), 1 influenza B (by both RT-PCR and culture) and 1 co-infection of HMPV and adenoavirus (by a combination of RT-PCR and culture).

3.4. Characteristics of viral infections

Due to the small number of subjects with confirmed viral etiologies, three groups were considered for analysis: HRSV-positive, other virus-positive and virus-negative patients (Table 2). The mean age at the time of NPA (7.4, 7.6 and 9.2 months for the three groups, respectively; p = 0.97) and the mean interval between onset of symptoms and collection of NPA (5.5, 3.9 and 5.9 days for the three groups, respectively; p = 0.32) were similar for the three groups when all visits were considered. There were no significant differences between the groups for the presence of cough (p = 0.10) and wheezing (p = 0.41), but HRSV-positive children had significantly less fever (p = 0.01) than children in the other two groups. Compared to children with other viral infections, HRSV-infected subjects had more bronchiolitis (73% vs 36%, p = 0.07), but less URTI (36% vs 77%, p = 0.05). There were only three palivizumab-treated children with confirmed pneumonitis (one was positive for HMPV and two had no virus detected). Among the 14 hospitalized children, one each had HRSV, HMPV, adenoavirus and influenza B infections and 10 had no viral etiologies.

3.5. Specific characteristics of HRSV-positive children on palivizumab

A total of 11 NPAs were positive for HRSV from 10 children (subject 002 had two positive NPAs during consecutive visits 5 days apart) (Table 3). Thus, 8.6% (10/116) of all recruited infants on palivizumab, or 20% (10/50) of those who consulted or were hospitalized for ARTI, were positive for HRSV. These HRSV infections occurred throughout the study period with cases from the end of January to the end of April. By comparison, the peak of HRSV activity in the Province of Quebec during the same year extended from
### Table 2
Clinical features of subjects on palivizumab with HRSV infections or other viral infections

|                      | HRSV | Other viral infectionsa | No virus detected |
|----------------------|------|-------------------------|------------------|
|                      | All visits | Outpatient consultations | Hospitalizations | All visits | Outpatient consultations | Hospitalizations | All visits | Outpatient consultations | Hospitalizations |
| Mean age at the time of NPA (months) | 7.4 (n = 11) | 7.8 (n = 10) | 3.6 (n = 1) | 7.6 (n = 22) | 7.7 (n = 19) | 6.5 (n = 3) | 9.2 (n = 57) | 7.8 (n = 47) | 15.6 (n = 10) |
| Mean interval between symptoms onset and NPA (days) | 5.5 (n = 11) | 5.1 (n = 10) | 9 (n = 1) | 3.9 (n = 22) | 3.7 (n = 19) | 5.3 (n = 3) | 5.9 (n = 57) | 5.8 (n = 47) | 6.3 (n = 10) |

**Feverb (%)**
- HRSV: 9.1 (n = 11)
- Other viral infections: 10 (n = 10)
- No virus detected: 0 (n = 1)

**Cough (%)**
- HRSV: 100 (n = 11)
- Other viral infections: 100 (n = 10)
- No virus detected: 0 (n = 1)

**Wheezing (%)**
- HRSV: 45.5 (n = 11)
- Other viral infections: 50 (n = 10)
- No virus detected: 0 (n = 1)

**Bronchiolitis (%)**
- HRSV: 72.7 (n = 11)
- Other viral infections: 70 (n = 10)
- No virus detected: 100 (n = 1)

**Pneumonitis (%)**
- HRSV: 0 (n = 11)
- Other viral infections: 0 (n = 10)
- No virus detected: 0 (n = 1)

**Croupb (%)**
- HRSV: 9.1 (n = 11)
- Other viral infections: 10 (n = 10)
- No virus detected: 0 (n = 1)

**Otitis media (%)**
- HRSV: 9.1 (n = 11)
- Other viral infections: 0 (n = 10)
- No virus detected: 0 (n = 1)

**Pharyngitis (%)**
- HRSV: 9.1 (n = 11)
- Other viral infections: 0 (n = 10)
- No virus detected: 0 (n = 1)

**Flu-like illnessb (%)**
- HRSV: 0 (n = 11)
- Other viral infections: 0 (n = 10)
- No virus detected: 0 (n = 1)

**Note:** URTI: upper respiratory tract infection; NPA: nasopharyngeal aspirate; HRSV: human respiratory syncytial virus.

a Infections with influenza A or B, parainfluenza viruses, human metapneumovirus and adenoviruses.

b p < 0.05 by comparing the three study groups.

the beginning of February until mid-March (data not shown). Seven of the 10 HRSV-positive subjects received palivizumab because of prematurity of <33 weeks of gestation, whereas three were born at 33 weeks of gestation and had other risk factors. The mean age of the ten HRSV-positive subjects at the time of first NPA collection was 7.5 months (median: 7.1, range: 3.6–11.7 months) and these children had received a mean of 5.3 doses of palivizumab (median: 5.5, range: 4–7). The mean interval of time between the last dose of palivizumab and detection of HRSV was 16.3 days (median: 14, range: 6–28 days). Seven (70%) of the 10 HRSV-positive subjects had a diagnosis of bronchiolitis although only one (10%) was hospitalized for a period of 7 days (Table 3). This child developed a bronchiolitis that necessitated supplemental oxygen 10 days after the fourth palivizumab injection.

Genotyping of the 11 HRSV strains from 10 subjects revealed the presence of 6 group B and 5 group A strains. Sequence analysis of the HRSV F protein genes amplified directly from clinical specimens (except for strain 029 amplified from the viral isolate) revealed the presence of a few non-silent mutations (Table 3). Notably, the HRSV B strain from patient 038 contained an amino acid change at codon 272 (K/E), which is a part of the known binding epitope for palivizumab (Zhao et al., 2004a). This child received the highest number of palivizumab doses (7) and had a non-complicated bronchiolitis that did not necessitate hospitalization.

4. Discussion

Approximately 10% (10/116) of children receiving palivizumab prophylaxis in the cohort studied experienced HRSV infections severe enough for their parents to seek medical attention during the 2004–2005 season. Although, 7 of these HRSV-positive children had a diagnosis of bronchiolitis, most cases were mild and only one child (10%) required hospitalization. HRSV infections occurred after a significant number of doses of palivizumab (median of 5.5 doses) and relatively shortly after a dose (median of 14 days). Most cases of HRSV infection could not be explained by the emergence of resistance to palivizumab with the possible exception of one child.

Palivizumab is a humanized neutralizing immunoglobulin G1 monoclonal antibody directed against the F protein of HRSV that is approved for the prevention of severe HRSV infections in high-risk children (The IMpact-RSV Study Group, 1998). Cotton rat studies showed that mean serum levels of palivizumab of 40 μg/ml resulted in a 2-log (99%) reduction of HRSV titers in lungs (Johnson et al., 1997, 1999). The protective effect of palivizumab was confirmed in a large multicenter clinical trial of 1502 high-risk children who received monthly antibody administration. This study demonstrated a 55% reduction in HRSV-related hospitalization (The IMpact-RSV Study Group, 1998). The protective effect of palivizumab was also confirmed in a subgroup of young children with hemodynamically significant congenital heart disease (Feltes et al., 2003).

We systematically assessed the viral etiologies and clinical outcome associated with both upper and lower respiratory tract infections (severe enough to warrant medical consultation) in 116 high-risk patients who received palivizumab during the 2004–2005 winter season. Approximately 2/3 of these children were born prematurely before 33 weeks of gestation and 44% had an underlying disease. The mean number of palivizumab doses received was 5.7 per child and...
### Table 3

Characteristics of children with HRSV infections while on palivizumab

| Patient Visit | Age (months) | Date of NPA | # Doses before NPA | Time since last dose (days) | Age at birth (weeks) | Diagnosis | Hospitalization (days) | Cult. RT-PCR | Amino acid change (F gene) |
|--------------|-------------|-------------|--------------------|---------------------------|---------------------|-----------|------------------------|-------------|-------------------------|
| 002          | 6           | 01-26-2005  | 4                  | 15                        | 31.6                | Bronchiolitis   | No                     | + (B)       | –                      |
| 002          | 7           | 01-31-2005  | 4                  | 20                        | 31.6                | Bronchiolitis   | No                     | –           | + (A)                  |
| 010          | 6           | 02-04-2005  | 6                  | 8                         | 33.1                | URTI           | No                     | + (A)       | –                      |
| 022          | 6           | 03-16-2005  | 6                  | 8                         | 30.3                | Bronchiolitis, AOM | No                     | + (B)       | –                      |
| 029          | 6           | 04-05-2005  | 6                  | 28                        | 32.7                | Bronchiolitis   | No                     | + (B)       | –                      |
| 038          | 6           | 05-06-2005  | 7                  | 23                        | 32.7                | URTI           | No                     | + (B)       | –                      |
| 045          | 6           | 06-07-2005  | 7                  | 28                        | 26.4                | Croup          | No                     | + (B)       | –                      |
| 052          | 6           | 07-08-2005  | 7                  | 26                        | 32.9                | Bronchiolitis   | No                     | + (B)       | –                      |
| 058          | 6           | 08-09-2005  | 8                  | 28                        | 33.4                | Bronchiolitis   | No                     | + (A)       | 157 (N/D)              |
| 062          | 3           | 02-18-2005  | 4                  | 10                        | 33.7                | Bronchiolitis   | Yes (7)                | + (A)       | –                      |

Note: URTI: upper respiratory tract infection; AOM: acute otitis media; NPA: nasopharyngeal aspirate.

An unexpected result of this study was the timing of HRSV infections in our palivizumab-treated children. As shown in Table 3, all HRSV infections occurred after a minimum of 4 doses of palivizumab (median 5.5) and a median of 14 days after the last dose. These breakthrough infections could not be explained by more intense viral circulation in the community since they occurred throughout the study period. Previous studies have shown that mean trough serum antibody concentrations increase with the number of palivizumab doses to reach 72 μg/ml after the fourth dose (The IMpact-RSV Study Group, 1998) and that levels of serum neutralizing antibody titers are good correlates of protection against HRSV (Piedra et al., 2003). An explanation for the occurrence of such HRSV infections may be that inadequate antibody levels were present in some children. Alternatively, palivizumab could have lost neutralizing activity due to emergence of specific viral mutations or other factors, such as specific cell-mediated immunity, may be involved in protection against HRSV infections.

In vitro and animal studies for selection of palivizumab-resistant HRSV escape mutants have revealed a critical region encompassing amino acids 262–276 of the F protein (Beeler and van Wyke Coelingh, 1989; Zhao et al., 2004a,b; Zhao and Sullender, 2005). In particular, mutations at codon 272 (Lys → Met, Gln) and codon 268 (Asn → Ile) were associated with complete and partial in vitro resistance, respectively, to palivizumab. Of note, only the 272 mutants were associated with resistance to infused antibody in cotton rats (Zhao et al., 2004a,b; Zhao and Sullender, 2005). To date, there have been no reports of palivizumab-resistant HRSV strains in children, although only a limited number of viruses from infants receiving prophylaxis have been evaluated (DeVincenzo et al., 2004; Johnson et al., 1997). Of the 6 F protein amino acid changes found in our study, only one (Lys 272 Glu) was located in the putative drug-binding site.
site and could potentially confer resistance to palivizumab. This mutant virus was selected after 7 doses of palivizumab and did not grow initially in cell culture (only RT-PCR was positive). Furthermore, the infected child had an uneventful bronchiolitis. These facts could suggest that this mutant virus had decreased viral fitness or that the antibody was still partially effective. Additional work is also required to evaluate the potential of a new humanized monoclonal antibody derived from palivizumab (Motavizumab, MedImmune Inc.), with a 70-fold increase in binding affinity, against some palivizumab-resistant strains (Mejias et al., 2005). The relevance of the other HRSV F protein changes detected in our study is unclear. A comparative analysis of our strains with 41 HRSV A and 15 HRSV B F protein sequences available in GenBank showed that only the Ser485Phe mutation had previously been reported in only one other HRVS A isolate (data not shown).

Our study has some limitations. First, we had no control (untreated) group to compare viral etiologies and outcomes with our palivizumab recipients. However, the inclusion of such subjects would have been unethical at the time of this study. Second, only a small percentage (36%) of ARTI had a confirmed viral etiology, which probably reflects the absence of specific RT-PCR assays to detect rhinoviruses, coronaviruses and human bocavirus. Also, we did not perform palivizumab neutralization studies for the HRVS strains detected in our study. Lastly, not all eligible patients were enrolled in our study (10% of parents did not give consent mostly because they were living too far away from the clinic) and this could have introduced a bias in our results.

In conclusion, we showed that while HRVS remains a major cause of ARTI in children receiving palivizumab prophylaxis, the clinical outcome of the 10 HRVS-infected children we studied was generally mild. Future work is required to further evaluate the development of HRVS infections in children receiving multiple doses of palivizumab and to determine the additional benefits of more potent antibodies.

Acknowledgment

This study was supported by MedImmune Inc. (Gaithersburg, MD).

References

Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989;63:2941–50.

Boivin G, De Serres G, Cote S, Gilica R, Abed Y, Rochette L, Bergeron MG, Dery P. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003;9:634–40.

DeVincenzo IP, Hall CB, Kimberlin DW, Sanchez PJ, Rodriguez WI, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004;190:975–8.

Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top Jr FH, Connor EM, Sondheimer HM. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–40.

Greenough A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr Opin Pulm Med 2002;8:214–7.

Hamelin ME, Cote S, Lafarge J, Lampron N, Bourbeau J, Weiss K, Gilica R, DeSerres G, Boivin G. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:498–502.

The IMPACT-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–7.

Jarti T, van den Hoogen B, Garofalo RP, Osterhaus AD, Ruuskanen O. Metapneumovirus and acute wheezing in children. Lancet 2002;360:1393–4.

Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 1999;180:35–40.

Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O’Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215–24.

Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003;22:S40-4.

Mejias A, Chavez-Bueno S, Rios AM, Aten MF, Raynor B, Peromingo E, Soni P, Olsen KD, Kiener PA, Gomez AM, Jafari HS, Ramilo O. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005;49:4700–7.

Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004;5:519–26.

Piedra PA, jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003;21:3479–82.

Thompson WW, Shay DK, Weintraub E, Bramer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–86.

Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 2003;22:S6–12.

Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, Wright PF, Crowe Jr JE. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350:443–50.

Zha X, Chen FP, Megaw AG, Sullender WM. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 2004;190:975–8.

Zha X, Chen FP, Sullender WM. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004b;318:608–12.

Zha X, Sullender WM. In vivo selection of respiratory syncytial virus resistant to palivizumab. J Virol 2005;79:3962–8.